Treatment of Colonic Obstruction With Cook Evolution® Colonic Stent System
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Ontario
-
Kingston, Ontario, Canada, K7L5G2
- Kingston General Hospital
-
Toronto, Ontario, Canada, M5B1N8
- St. Michael's Hospital
-
-
-
-
-
Odense, Denmark, 5000
- Odense Universitetshospital
-
-
-
-
-
Marseille, France, 13009
- Institut Paoli Calmettes
-
-
-
-
-
Milan, Italy, 20089
- Instituto Clinico Humanitas Irccs
-
-
-
-
-
Deventer, Netherlands, 7416 SE
- Deventer Ziekenhuis
-
-
-
-
-
Bilbao, Spain, 48013
- Hospital de Basurto
-
Girona, Spain, 17007
- Hospital Universitari de Girona
-
Palma de Mallorca, Spain, 48013
- Hospital Son Llatzer
-
-
-
-
-
London, United Kingdom, NW 1 2BU
- University College of London Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion: per the IFU,
- colonic strictures caused by malignant neoplasms, and
- large bowel obstruction due to malignant strictures prior to colectomy.
Exclusion:
- central ischemia,
- any contraindication to GI endoscopy and any procedure to be performed in conjunction with stent placement,
- suspected or impending perforation,
- intra-abdominal abscess/perforation,
- inability to pass wire guide or stent deployment system through the obstructed area,
- patients for whom endoscopic or percutaneous procedures are contraindicated,
- benign disease, and
- coagulopathy.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Stent Group
|
Palliative treatment of colonic obstruction or strictures caused by malignant neoplasms and to relieve acute large bowel obstruction prior to colectomy in patients with malignant strictures.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Relief of obstruction
Time Frame: At the Conclusion of the Procedure
|
At the Conclusion of the Procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implant Duration
Time Frame: 6 months
|
6 months
|
|
|
Symptoms at Follow-up
Time Frame: 6 months
|
6 months
|
|
|
Complications
Time Frame: 6 months
|
perforation, migration, obstruction, GI bleeding requiring intervention
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 09-022
- 100041 (Cook)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.